The molecular mechanism of prostate cancer chemo-prevention agents with androgen receptor.
Project/Area Number |
25462484
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Urology
|
Research Institution | Kyushu University |
Principal Investigator |
Akira Yokomizo 九州大学, 医学(系)研究科(研究院), 准教授 (60346781)
|
Project Period (FY) |
2013-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Keywords | 前立腺癌 / 化学予防 / 分子生物学 |
Outline of Final Research Achievements |
To reveal the molecular mechanisms of chemoprevention of prostate cancer, we focused on aspirin, celecoxib and equol (isoflavone). We identified that prostaglandin receptor EP3 mediates growth inhibitory effect of aspirin through androgen receptor and contributes to castration resistance in prostate cancer cells. Furthermore, EP2 signaling mediates suppressive effects of celecoxib on androgen receptor expression and cell proliferation in prostate cancer. Finally, equol augments Skp2-mediated androgen receptor degradation. These findings will contribute to chemoprevention for prostate cancer.
|
Report
(3 results)
Research Products
(10 results)
-
[Journal Article] Equol inhibits prostate cancer growth via degradation of the androgen receptor by Skp2.2016
Author(s)
Itsumi M, Shiota M, Takeuchi A, Kashiwagi E, Inokuchi J, Tatsugami K, Kajioka S, Uchiumi T, Naito S, Eto M, Yokomizo A.
-
Journal Title
Cancer Sci
Volume: in press
Pages: 327-331
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research / Acknowledgement Compliant
-
[Journal Article] Potential Role for YB-1 in Castration-Resistant Prostate Cancer and Resistance to Enzalutamide Through the Androgen Receptor V7.2016
Author(s)
Shiota M, Fujimoto N, Imada K, Yokomizo A, Itsumi M, Takeuchi A, Kuruma H, Inokuchi J, Tatsugami K, Uchiumi T, Oda Y, Naito S.
-
Journal Title
J Natl Cancer Inst.
Volume: 108
Issue: 7
Pages: djw005-djw005
DOI
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
-
-
-
-
[Presentation] Equol promotes protein degradation of androgen receptor via Skp2 and suppressed cell proliferation in prostate cancer2015
Author(s)
Mmoe Itsumi, Masaki Shiota, Akira Yokomizo, Eiji Kashiwagi, Aro Takeuchi, Kenjiro Imada, Katsunori Tatsugami, Junichi Inokuchi, Takeshi Uchiumi, Shunichi Kajioka, Seiji Naito
Organizer
第74回日本癌学会学術総会
Place of Presentation
名古屋国際会議場
Year and Date
2015-10-08
Related Report
Int'l Joint Research
-
[Presentation] Isoflavons, daidzein and equol, are involved in the biology of prostate cancer2014
Author(s)
Momoe Itsumi, Masaki Shiota, Akira Yokomizo, Eiji Kashiwagi, Ario Takeuchi, Keijiro Imada, Katsunori Tatsugami, Junichi Inokuchi, Takeshi Uchiumi, Seiji Naito
Organizer
The 4th Asian Pacific Prostate Society in Okinawa
Place of Presentation
沖縄県 ブセナテラス
Related Report
-
-